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Abstract
Backgroud: Multiple endocrine neoplasia type 2A (MEN2A) is a condition with inherited autosomal dominant mutations in RET
(rearranged during transfection) gene that predisposes the carrier to extremely high risk of medullary thyroid cancer (MTC) and other
MEN2A-associated tumors such as parathyroid cancer and/or pheochromocytoma. Little is reported about MEN2A syndrome in the
Chinese population.
Methods: All members of the 3 families along with specific probands of MEN2A were analyzed for their clinical, laboratory, and
genetic characteristics. Exome sequencing was performed on the 3 probands, and specific mutation in RETwas further screened on
each of the family members.
Results:Different mutations in theRET genewere identified: C634S in Family 1, C611Y in Family 2, and C634Y in Family 3. Proband
1 mainly showed pheochromocytoma with MTC, both medullary thyroid carcinoma and pheochromocytoma were seen in proband
2, and proband 3 showed medullary thyroid carcinoma.
Conclusion: The genetic evaluation is strongly recommended for patients with a positive family history, early onset of age, or multiple
sites ofmasses. If the results verified themutations ofRET gene, thyroidectomy should be undertaken as the guide for better prognosis.
Abbreviations: ALD = aldosterone, CEA = carcinoembryonic antigen, CT = computed tomography, FMTC = familial medullary
thyroid carcinoma, GFRa = GDNF-family receptor alpha, H&E = hematoxylin and eosin, MAX =MYC associated factor X, MEN2A =
multiple endocrine neoplasia type 2A, MN = noradrenaline, MTC = medullary thyroid cancer, NF1 = neurofibromin 1, PCT-1 =
procalcitonin, PTH = parathyroid hormone, RET = rearranged during transfection, SDHAF2 = succinate dehydrogenase complex
assembly factor 2, SDHB = succinate dehydrogenase subunit B, SDHC = succinate dehydrogenase subunit C, SDHD = succinate
dehydrogenase subunit D, VHL = Von Hippel–Lindau, VMA = vanillylmandelic acid.
Keywords: medullary thyroid carcinoma, multiple endocrine neoplasia type 2A, pheochromocytoma, RET gene mutation
1. Introduction
Multiple endocrine neoplasia type 2 (MEN2) is an autosomal
dominant inherited syndrome, affecting about 1 in 30,000
individuals.[1] MEN2 can be categorized into 3 subtypes:
MEN2A, MEN2B, and familial medullary thyroid carcinoma
(FMTC). MEN2A is characterized by medullary thyroid
carcinoma, pheochromocytoma, and primary hyperparathyroid-
ism. MEN2B is defined by the presence of medullary thyroid
carcinoma, pheochromocytoma, marfanoid habitus, mucosal
neuromas, and ganglioneuromatosis of the gut and intestine.
FMTC is associated with simple medullary thyroid carcinoma.
All MEN2 cases occur due to the RET (rearranged during
transfection) gene mutations. Of these, more than 95% of
MEN2A cases present a single point mutation in theRET gene.[2]
The protooncogene RET, residing on chromosome 10q11.2 with
21 exons, encodes a transmembrane receptor tyrosine kinase[3]
with 3 functional domains: an extracellular ligand-binding
domain, a transmembrane domain, and a cytoplasmic tyrosine
kinase domain. As a response to specific ligand stimulation, RET
dimerizes and interacts with coreceptors, GDNF-family receptor
alpha (GFRa1–GFRa4).[4] The intracellular domain, which
contains 2 tyrosine kinase subdomains, is involved in several
downstream intracellular signal transductions, including the
PI3K–AKT andMAPK–ERK kinase signaling pathways.[5] In the
wild-type RET, phosphorylation of its tyrosine kinase domain
stimulates the receptor and consequently the downstream
signaling pathways. However, nucleotide mutations in 7 exons
(exons 8, 10, 11, 13, 14, 15, or 16) of the RET gene resulting in
Cys to Tyr in the RET protein have been found. All these gain-of-
function mutations lead to a constitutive activation of RET,[6]
which consequently causes hyperplasia and cancerization of the
affected cells.
Although multiple endocrine neoplasia type 2A (MEN2A) can
result in medullary thyroid carcinoma, pheochromocytoma, or
primary hyperparathyroidism alone or combination, not all
MEN2A patients show similar symptoms. Results from different
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studies collectively indicate that diverse phenotypes are highly
related to the site of the mutation. For example, substitution of
Met918Thr in the tyrosine kinase domain is responsible for
MEN2B.[7,8] Any 1 of the 5 cysteine residues (609, 611, 618, 620,
and 634) in the cysteine-rich region of the RET extracellular
domain can cause MEN2A and FMTC.[3,9] Nevertheless,
alterations in the downstream pathways also contribute to
diverse phenotypes. Little is reported aboutMEN2A syndrome in
the Chinese population. Herein, we present the findings of
different RET gene mutation-induced MEN2A in 3 Chinese
families with diverse medical histories, as well as clinical,
laboratory, and genetic characteristics.
2. Materials and methods
2.1. Patients
Proband 1 is a 19-year-old male suffering from chronic dizziness
and palpitation for about half a year. A computed tomography
(CT) scan revealed a suprarenal mass approximately 4.3cm in the
left abdominal area (Fig. 1A). The calcitonin level was also
elevated, suggesting an abnormality in the thyroid. The genetic
evaluation identified a mutation in the RET gene. In addition,
bilateral pheochromocytomas and medullary thyroid cancer
(MTC) had been diagnosed in the proband’s father who is
currently 59-years-old. Since the parathyroid hormone (PTH)
level in the father was high, hyperparathyroidism was suspected,
and further examination found a rare ectopic pheochromocyto-
ma in his abdomen. He was found to carry the same mutation as
proband 1. Further genetic tests on the other family members
found the same mutation in proband’s half-brother, who is
currently 27-years-old but does not show any MEN2-related
abnormality.
Proband 2 is a 42-year-old female whowas admitted to Daping
Hospital of Third Military Medical University Hospital in
November 2013 for the elucidation of the cause of headache and
dizziness over a period of 1 year. The blood pressure was 220/
110mm Hg, and Amlodipine Besylate tablet was prescribed for
oral administration. A CT scan discovered bilateral adrenal
(Fig. 1B) and thyroid (Fig. 1C and D) masses. The genetic test
identified a different mutation in the RET gene. The 44-year-old
sister of proband 2 was diagnosed with MTC and pheochromo-
cytoma several years ago, following which, thyroidectomy was
conducted. However, due to the incomplete procedure, the tumor
Figure 1. CT of the probands: (A) CT enhancement scan of the abdomen in proband 1. (B) CT enhancement scan of the abdomen in proband 2. (C) CT scan of the
thyroid in proband 2. (D) CT enhancement scan of the thyroid in proband 2. (E) CT scan of the thyroid in proband 3. (F) CT enhancement scan of the thyroid in
proband 3.
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recurred in the thyroid, and a total thyroidectomy was
performed. As described later, she also carried the same mutation
as proband 2. A mass was also found in the thyroid of the
probands mother, who is 65-years-old with increased calcitonin
and carried the same mutation. However, the son, currently 17-
years-old, also carried the same mutation but did not show any
MEN2-related abnormality.
Proband 3 is a 35-year-old female admitted to our hospital for
the carcinoembryonic antigen (CEA) at 204.06ng/mL. CT and
PET-CT scans revealed masses on the left thyroid (Fig. 1E and F)
and enhanced lymph node along the left sternocleidomastoid
muscles. Genetic analysis revealed a mutation in the RET gene,
which was different from that in probands 1 and 2. The paternal
uncle of proband 3, currently 55-years-old suffered from MTC
18 years earlier. As discussed below, he also carried the same
mutation as proband 3, suggesting that the father of the proband
likely harbors the same mutation. However, he did not yet
display any MEN2-related abnormality.
2.2. Ethical review and patient consent
The Institutional Review Board of Daping Hospital of Third
Military Medical University waived the IRB approval for the
study; however, the written informed consent was obtained from
the patients for the use of medical records and related images,
before the publication of the study.
2.3. Laboratory and pathological examinations
When MEN2A was suspected, a series of examinations were
undertaken, including levels of calcitonin, PCT-1 (procalcitonin),
PTH, VMA (vanillylmandelic acid), MN (noradrenaline), and
ALD (aldosterone). The cortisol levels were monitored for 24 at 8
h intervals. Moreover, whole-body CT scanning was conducted
for potential tumors. In the event that tumors were identified,
resected tumor tissues were submitted to the licensed pathologist
for confirmation of the lesions. All the tissues were embedded in
paraffin, sectioned, deparaffinized, and analyzed by the standard
hematoxylin and eosin (H&E) staining procedures.
2.4. Mutation analysis of RET
Total DNA isolated from the peripheral blood of all the probands
was used for screening the potential mutations in the following
genes: SDHAF2 (succinate dehydrogenase complex assembly
factor 2), SDHB (succinate dehydrogenase subunit B), SDHC
(succinate dehydrogenase subunit C), SDHD (succinate dehy-
drogenase subunit D), MAX (MYC associated factor X), NF1
(neurofibromin 1), RET, and VHL (Von Hippel–Lindau) using
Target Capture-Based Deep Sequencing (BGI Health, Shenzhen,
Guangdong, China). Upon identification of the mutation, the
same putative mutations in themembers of the probands’ families
were tested.
3. Results
3.1. Clinical features of the 3 probands
The characteristics of the 3 probands identified in this study are
summarized in Table 1. In addition, the masses in the adrenal
and/or thyroid were confirmed by CT scans (Fig. 1), and the
postoperative pathological examinations further verified the
diagnoses (Fig. 2). A pheochromocytomawas identified in the left
Table 1
The laboratory parameters of the probands.
Proband 1 Proband 2 Proband 3
Time of operation 2015-3-10 2015-3-6 for the first time, 2015-5-8 for the second time 2015-5-12
Cacitonin 8.58 (2015-4-16), 11.7 (2015-8-5),
28.53 (2015-12-23)
2062.7 (2015-5-7), 74.95 (2015-5-14),
15.84 (2015-6-24), 619.3 (2015-9-23)
611.2 (2015-5-21), 860.2 (2015-6-23),
650.0 (2015-10-30), 408.1 (2015-11-17)
PTH 30.87 (2015-4-16), 15.08 (2015-8-5),
30.37 (2015-12-23)
36.10 (2015-5-7), 2.91 (2015-5-14),
14.41 (2015-6-24)
4.99 (2015-5-21), 5.06 (2015-11-17)
PCT-1 0.28 (2015-3-9) 3.71 (2015-3-5), 3.98 (2015-5-7) —
VMA 83.2 (2015-3-9) 107.8 (2015-3-5) —
MN 5.2 (2015-3-9) 5.50 (2015-3-5) —
Cor8 272 (2015-3-9) 280.0 (2015-3-5) —
Cor16 177 (2015-3-9) 219.0 (2015-3-5) —
Cor24 75 (2015-3-9) 116.0 (2015-3-5) —
Orthostatic ALD 0.25 (2015-3-9) 0.14 (2015-3-5) —
Clinostatism ALD 0.21 (2015-3-9) 0.12 (2015-3-5) —
CEA 2.74 (2015-3-9) 38.81 (2015-3-5), 13.45 (2015-6-24),
11.23 (2015-9-23)
204.06 (2015-5-1), 32.46 (2015-10-30),
37.45 (2015-11-17)
hTSH — 1.58 (2015-3-5),0.74 (2015-5-7), 35.36 (2015-5-14),
4.27 (2015-6-24), 2.03 (2015-9-23)
2.12 (2015-5-1), 12.36 (2015-5-21),
0.15 (2015-6-23), 0.04 (2015-11-17)
FT3 — 3.61 (2015-3-5), 3.51 (2015-5-7), 3.18 (2015-5-14),
3.91 (2015-6-24), 4.20 (2015-9-23)
5.26 (2015-5-1), 2.21 (2015-5-21),
5.06 (2015-6-23), 4.72 (2015-11-17)
FT4 — 10.32 (2015-3-5), 14.03 (2015-5-7), 8.74 (2015-5-14),
16.61 (2015-6-24), 12.50 (2015-9-23)
12.78 (2015-5-1), 5.86 (2015-5-21),
14.38 (2015-6-23), 14.78 (2015-11-17)
T3 — 1.51 (2015-3-5), 0.85 (2015-5-7), 0.84 (2015-5-14) 1.6 (2015-5-1), 0.63 (2015-5-21),
1.89 (2015-6-23), 1.49 (2015-11-17)
T4 — 85.94 (2015-3-5), 84.26 (2015-5-7), 67.23 (2015-5-14) 106.22 (2015-5-1), 34.12 (2015-5-21),
153.25 (2015-6-23), 124.97 (2015-11-17)
TG-Ab — 0.00 (2015-3-5), 0.00 (2015-5-7), 0.00 (2015-5-14) 0.80 (2015-5-1), 0.50 (2015-5-21),
0.00 (2015-6-23), 0.00 (2015-11-17)
ALD= aldosterone, CEA= carcinoembryonic antigen, Cor= cortisol, FT3= free triiodothyronine, FT4= free thyroxine, hTSH=human thyroid-stimulating hormone, MN=noradrenaline, PCT-1=procalcitonin,
PTH=parathyroid hormone, T3= triiodothyronine, T4= thyroxine, TG-Ab= throglobulin antibody, VMA= vanillylmandelic acid.
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adrenal gland of proband 1 (Fig. 2A). The pheochromocytoma in
proband 2 is shown in Fig. 2B and C; the medullary thyroid
carcinoma is shown in Fig. 2D, and a positive lymph node in the
neck is shown in Fig. 2E and F. In the case of proband 3, theMTC
and positive lymph nodes are shown in Fig. 2G–I.
3.2. Identification of mutations in RET gene
Among all the genes screened, including SDHAF2, SDHB, SDHC,
SDHD, MAX, NF1, VHL, and RET, mutations have only been
identified in RET for all the 3 probands. Notably, the sites and/or
substitutions of the mutations among the 3 families were different.
The mutation in the RET gene in proband 1 was Cys634Ser
(Fig. 3A), proband 2 resented Cys611Tyr (Fig. 3B), whereas
proband 3 harbored a Cys634Tyr (Fig. 3C) mutation. Further-
more, after themutationhadbeen identified, all the familymembers
of the probands were screened to substantiate if they carried the
samemutation. Additional screening found that the father and one
of thehalf-brothers also carried the samemutation asproband1.As
mentioned earlier, bilateral pheochromocytomas and MTC had
been diagnosed in the proband’s father who is currently 59-years-
old. Since his PTH level was high, hyperparathyroidism was
suspected, and further examination found a rare ectopic
pheochromocytoma in his abdomen. However, the half-brother
with the same mutation who did not show any MEN2-related
abnormality. Further screening of the proband 2’s family members
found that her mother, son, and one of her sisters carried the same
mutation. Proband 2’s 44-year-old sister was diagnosedwithMTC
and pheochromocytoma several years ago, and thyroidectomywas
conducted. However, due to incomplete thyroidectomy, the tumor
recurred in the thyroid, followingwhich, she underwent a complete
procedure.Amasswas also found in the thyroidof themother,with
increased calcitonin. However, the son showed no MEN2-related
abnormality. The paternal uncle of proband 3 suffered fromMTC
before 18 years. He also carried the same mutation as proband 3,
suggesting that the father of proband 3 putatively harbored the
same mutation. However, any MEN2-related abnormity was not
yet observed. In these 3 families, other familymembers without the
mutation did not exhibit any MEN2A phenotype.
3.3. Diverse phenotypes of patients with RET mutations
The probands, as well as their family members carrying the RET
gene mutations, were shown with their family pedigrees (Fig. 4).
Figure 2. Pathological features of the probands: (A) Pathological biopsy of left adrenal pheochromocytoma stained with H&E (100) in proband 1. (B) Pathological
biopsy of left adrenal pheochromocytoma stained with H&E (100) in proband 2. (C) Pathological biopsy of right adrenal pheochromocytoma stained with H&E
(100) in proband 2. (D) Pathological biopsy of MTC stained with H&E (100) in proband 2. (E) Pathological biopsy of positive lymph node in the neck stained with
H&E (40) in proband 2. (F) Pathological biopsy of positive lymph node in the neck stained with H&E (100) in proband 2. (G) Pathological biopsy of MTC stained
with H&E (100) in proband 3. (H) Pathological biopsy of positive lymph node in the neck stained with H&E (40) in proband 3. (I) Pathological biopsy of positive
lymph node in the neck stained with H&E (100) in proband 3.
Liu et al. Medicine (2017) 96:3 Medicine
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In addition, the diverse phenotypes and related clinical informa-
tion of the probands and their families are summarized in
Table 2. All the 3 mutations had been reported previously.[10–15]
In our cases, along with positive family history, the 3 different
mutations in RET genes displayed different spectrums of disease.
Proband 1 (Cys634Ser) mainly showed pheochromocytoma with
MTC being indicated, proband 2 (Cys611Tyr) presented MTC
and pheochromocytoma, whereas the only symptom of proband
3 (Cys634Tyr) was MTC. Interestingly, probands 1 and 3 both
had a young age onset while proband 2 showed multiple tumors
simultaneously. Therefore, we concluded that the cysteine
substitution by tyrosine was predisposed to induce MTC, which
metastasized easily while the cysteine substitution by serine was
inclined to induce pheochromocytoma. Moreover, the mutation
of residue 634 could induce lesions at an early age. Notably,
proband 1’s father presented with a parathyroid disease and a
rare ectopic pheochromocytoma.
4. Discussion
In this case report, we presented the clinical, laboratory, and
genetic characteristics of 3 Chinese families with different RET
gene mutation-induced MEN2A. The 3 probands harbor
Cys634Ser, Cys611Tyr, and Cys634Tyr mutations in the gene,
respectively. Paun et al[16] suggested that pheochromocytoma
rarely precedes the development of MTC and is the initial
manifestation of MEN2A. If the patients underwent regular
screening, pheochromocytoma typically becomes evident about
10 years later than C-cell hyperplasia or MTC.[17] Thus, it is
unusual for pheochromocytoma to be the first manifestation of
MEN2A, similar to our cases 1 and 2. The underlying causes of
different manifestations remain to be further elucidated.
Of the 3 RET gene mutation-induced MEN2A syndromes
reported in this study, 2 included the mutation on residue 634
and the third on residue 611; however, they showed diverse
phenotypes. What leads to these diversifications? Also, different
mutations could result in different degrees of RET activation.
Carlomagno et al[18] found that different phenotypes of MEN2A
and FMTC resulting from Cys-634 mutation of MEN2A could
lead to higher activity of RET as compared to Cys-620 mutation
of FMTC. On the other hand, diversified sensitivities of different
tissues and individuals to mutations activating RETmay also give
Figure 3. Mutations in RET gene in proband 1 (A), proband 2 (B), and proband
3 (C).
Figure 4. Family’s pedigrees of proband 1 (A), proband 2 (B), and proband 3 (C).
Liu et al. Medicine (2017) 96:3 www.md-journal.com
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rise to different phenotypes. For instance, thyroid C-cells may
have a low transformation threshold, being sensitive also to the
low activity of RET mutation. Conversely, the alteration of only
certain amino acids (634 in MEN2A and 918 in MEN2B)
effectuates a sufficiently high RET stimulation to cause a
neoplastic transformation of adrenal chromaffin cells,[18]
indicating that even in the MEN2A phenotype, pheochromocy-
tomas have been observed less frequently than MTCs.[19]
Although similar mutation in proband 2 and the family members
was noted, different phenotypes were observed. The proband and
her sister were diagnosed with metastasized MTC and adrenal
pheochromocytoma at about 40 years of age while their mother
was diagnosed with MTC at about 70 years of age. This
exhibition of phenotype at different ages could be attributed to
the proband and her sister showing increased sensitivity to the
Cys611Tyr mutation than their mother. Thus, the different
sensitivities could be related to the RET downstream pathway.
AKT was found to be activated in cells expressing RET-MEN2A,
which was PI3K-dependent. Moreover, the expression of
dominant-negative forms of AKT has been recently reported to
inhibit RET-MEN2A oncogenic activity,[20] indicating that the
second family members could harbor different AKT activities.
Notably, the mechanisms of the diverse phenotypes are extremely
complicated, necessitating further investigation.
The major manifestation of MEN2 is MTC. Patients with
MEN2 are posedwith a 70% to 100% risk of developingMTCby
the age of 70 years[21]; onceMTC spreads beyond the thyroid, the
prognosis is extremely poor. Therefore, a majority of the
treatments for MEN2 were focused on MTC.[22] For the same
reason, screening of RET mutation and prediction of MEN2 with
high-risk of pheochromocytoma should be carried out at the
earliest. Given the high penetrance of this disease, family members
of the patient should also be screened. In the case of MEN2A
patientswith earlymanifestationofpheochromocytoma, screening
and confirming the RET mutation followed by a timely treatment
at anearly stage is suggested toprevent thedevelopmentofMTC.A
consensus guideline for the diagnosis and management of
neuroendocrine tumors issued by North American Neuroendo-
crine Tumor Society suggests that RET mutation should be
classified by the locus of themutations thatmay serve as guidelines
for the treatment of MTC. In order to improve prognosis,
thyroidectomy should be conducted by 5 to 10 years of age in
children carrying theRETgenemutationsat codons609,630,768,
790, 791, 804, and 891 (referred as level 1). For patients with level
2 (mutations of codons 611, 618, 620, 634), operations should be
done by 5 years of age and for those with level 3 (mutations of
codons 883, 918, 922), thyroidectomy should be conducted in the
first month but no later than 6 months of life.
MEN2A has a poor prognosis with MTC developing silently to
its later stage. Therefore, screening, early diagnosis, and timely
treatment of this disease at the early stages are the key factors for a
better prognosis. In addition, early onset of the disease should also
raise suspicion on possible gene mutations. The appearance of
masses on multiple sites including simultaneousMTC and adrenal
pheochromocytoma or bilateral adrenal pheochromocytoma are
other indications of the disease. If a mutation in the gene is
suspected, next generation sequencing, which has beenwidely used
for the identification of rare causative mutations, should be
undertaken immediately. To collect all the pedigree data, the
membersof the proband shouldbe screened for potential carriers of
the mutation. Such a targeted screening could allow an efficient
utilization of bioinformatics information.[23] In addition, data from
knockout and/or transgenic animals[24] mimicking different
diseases including MEN1,[25] MEN2,[26] and MENX[27] demon-
strated that animal models are valuable for the enhanced
understanding of the molecular mechanisms in specific mutation-
caused diseases. Therefore, transgenicmice carrying each of these 3
mutationscouldbe establishedandused for studying theunderlying
mechanisms in RET gene mutation-induced MEN2A. Moreover,
we could use cell models with the corresponding mutations for the
functional analysis. We might also aspire to explore the diverse
functions andphenotypesby transfecting thyroidor chromaffin cell
lines with plasmids expressing different RET mutations.
In summary, by comparing the clinical, laboratory, genetic
characteristics, and diverse phenotypes of the 3 Chinese families
harboring different RET gene mutations, we conclude that
further application of genetic testing is essential in order to detect
the disease at a curable stage.
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